Artificial Intelligence: A Molecule For Alzheimer’s Created By Exscientia’s AI Enters Clinical Trials
The drug molecule, DSP-0038, was created by Exscientia in collaboration with Sumitomo Dainippon Pharma
Oxford, UK-based Exscientia uses AI to design and create drug candidate molecules satisfying complex therapeutic requirements with revolutionary efficiency. Joint research by Exscientia with Sumitomo Dainippon Pharma Co., Ltd. (TYO: 4506) resulted in the creation of the molecule DSP-0038, a dual-targeted 5-HT1A agonist and 5-HT2A antagonist to be assessed for treatment of Alzheimer’s disease psychosis. Sumitomo will now initiate a Phase 1 clinical study of DSP-0038 in the United States. (BusinessWire)
Third molecule created by Exscientia
Earlier, Exscientia’s AI technology created the DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma to treat obsessive-compulsive disorder, and Exscientia’s immuno-oncology agent, EXS-21546, announced earlier this year.
DSP-0038, for Alzheimer’s Disease, is the third molecule from the company and will be assessed for improved antipsychotic effects associated with Alzheimer’s disease psychosis, as well as improvements in behavioral and psychological symptoms of dementia which include agitation, aggression, anxiety, and depression.
Andrew Hopkins, CEO of Exscientia, said: “This is further validation that our AI platform can turn complex biological challenges into high-quality clinical candidates quickly. To have what we believe to be the world’s first three clinical molecules created using AI arising from our own platform – two with Sumitomo Dainippon Pharma – is a wonderful achievement. We hope that through the creation of DSP-0038 improved treatments for Alzheimer’s disease psychosis will be realized.”
Funding of up to $525 million
Exscientia announced last month that it had completed a $225 million Series D funding round with access up to an additional $300 million at the company’s discretion.
SoftBank Vision Fund 2 led the Series D and was joined by previous round lead investors, Novo Holdings, and funds managed by Blackrock.
Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou, and Bristol-Myers Squibb.
In addition, SoftBank provided an additional $300 million equity commitment that can be drawn at the Company’s discretion.
Related Story: Chemistry-combing AI Algo Discovers New Antibiotic
Latest Alternative Investment News
Alternative Investments/Digital: State Street Digital, A New Division At State Street, To Focus On Crypto
State Street (NYSE: STT), which has $40.3 trillion in assets under custody or administration, said Thursday it is establishing a new digital finance division called State Street Digital. The new…
United Airlines (NASDAQ: UAL) announced its new corporate venture fund, United Airlines Ventures, on Thursday. The fund’s brief is to invest in emerging companies that could reinvent travel and aviation…
The IMF warned Thursday that El Salvador’s move to adopt bitcoin as a legal currency in parallel with the US dollar could have various economic and legal repercussions. El Salvador’s…
Clip, a Mexican digital payments and commerce platform founded in 2012, announced June 10, its raise of $250 million in a round led by the SoftBank Latin America Fund and…